Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab.

LONDON, GREATER LONDON, UNITED KINGDOM, August 19, 2025 /EINPresswire.com/ -- Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry ...

CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.

The chronic lymphocytic leukemia therapeutics market is expected to grow at a compound annual growth rate of 7% from 2025 to ...

Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or ...